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Abstract
Background—Although depression is a risk factor for cardiovascular disease (CVD), it is 
unknown whether this risk varies across depressive disorder subtypes. Thus, we investigated 
atypical major depressive disorder (MDD) and double depression as predictors of new-onset CVD 
in a nationally representative sample of U.S. adults.
Methods—Prospective data from 28,726 adults initially free of CVD who participated in Wave 1 
(2001–2002) and Wave 2 (2004–2005) of the National Epidemiologic Survey on Alcohol and 
Related Conditions (NESARC) were examined. Lifetime depressive disorder subtypes (Wave 1) 
and incident CVD (Wave 2) were determined by structured interviews.
Results—We identified 1,116 incident CVD cases. In demographics-adjusted models, the 
atypical MDD group had a higher odds of incident CVD than the no depression history (OR=2.19, 
95% CI: 1.71–2.81, p<.001), dysthymic disorder only (OR=1.61, 95% CI: 1.08–2.39, p=.019), and 
nonatypical MDD (OR=1.46, 95% CI: 1.11–1.91, p=.006) groups. Likewise, the double 
depression group had a higher odds of incident CVD than the no depression history (OR=2.17, 
95% CI: 1.92–2.45, p<.001), dysthymic disorder only (OR=1.59, 95% CI: 1.16–2.19, p=.004), and 
MDD only (OR=1.46, 95% CI: 1.20–1.77, p<.001) groups. Relationships were similar but 
attenuated after adjustment for CVD risk factors and anxiety disorders.
Conclusions—Adults with atypical MDD or double depression may be subgroups of the 
depressed population at particularly high risk of new-onset CVD. Thus, these subgroups may (a) 
be driving the overall depression-CVD relationship and (b) be in need of earlier and/or more 
intense CVD primary prevention efforts to reduce their excess CVD burden.
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Introduction
Considerable evidence indicates that depression is an independent risk factor for 
cardiovascular disease (CVD) (Van der Kooy et al., 2007). However, it is unknown whether 
the CVD risk conferred by depression varies across disorder subtypes. Atypical depression 
accounts for 15–40% of depression cases, and among its key features are the reversed 
somatic-vegetative symptoms of hyperphagia and hypersomnia (APA, 2013; Grant et al., 
2009; Quitkin, 2002). Adults with atypical depression, compared to those with nonatypical 
depression, have higher rates or levels of several CVD risk factors, including dyslipidemia, 
hypertension, diabetes, obesity, metabolic syndrome, physical inactivity, and systemic 
inflammation (Chou & Yu, 2013; Cizza et al., 2012; Glaus et al., 2013; Hickman, Khambaty, 
& Stewart, 2014; Lamers et al., 2013; Lasserre et al., 2014; Levitan et al., 2012; Niranjan, 
Corujo, Ziegelstein, & Nwulia, 2012; Rudolf, Greggersen, Kahl, Huppe, & Schweiger, 2014; 
Takeuchi, Nakao, Kachi, & Yano, 2013; van Reedt Dortland et al., 2010). Because of this 
higher risk factor burden, atypical depression may be a stronger predictor of CVD than 
nonatypical depression. The few existing studies, however, do not support this notion. 
Niranjan and colleagues (2012) found no difference in prevalent CVD between depressed 
adults with versus without atypical features, and atypical MDD symptoms were not 
associated with prevalent CVD in two other studies (Fraguas et al., 2007; Vogelzangs et al., 
2010). A key limitation of all three studies, however, is their cross-sectional design, 
especially considering that reverse causality is plausible (Spijkerman et al., 2005) and could 
mask depression subtype differences.
Double depression refers to major depressive disorder (MDD) superimposed on dysthymia 
(Keller & Shapiro, 1982), a chronic, low-grade depressive disorder. About three quarters of 
patients with dysthymia have or will experience a major depressive episode and, thus, suffer 
from double depression (Hellerstein & Eipper, 2013). To date, associations of double 
depression with CVD risk markers or outcomes have not been examined. Nonetheless, 
double depression may be a stronger predictor of CVD due to its longer duration and higher 
recurrence rate than MDD alone and its greater symptom severity than dysthymia alone 
(Keller, Hirschfeld, & Hanks, 1997).
Because no studies have examined atypical or double depression as predictors of new-onset 
CVD, our primary aim was to address these key gaps. Our secondary aim was to evaluate 
whether these relationships are independent of anxiety disorders. As anxiety disorders are 
highly comorbid with depressive disorders (Kessler et al., 2003) and also predict incident 
CVD (Roest, Martens, de Jonge, & Denollet, 2010), it is important to adjust for them to 
isolate depression effects. We examined Wave 1 (2001–2002) and Wave 2 (2004–2005) data 
from a large, nationally representative sample of U.S. adults from the National 
Epidemiologic Survey on Alcohol and Related Conditions (NESARC).
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Materials and Methods
Study Design and Sample
NESARC is a prospective cohort study designed to determine the prevalence of alcohol use 
disorders and associated disabilities in the U.S. civilian noninstitutionalized population ≥18 
years. Descriptions of study methods are provided elsewhere (Grant, et al., 2009; Grant et 
al., 2005; Hasin & Grant, 2015). NESARC received ethical approval from the U.S. Census 
Bureau and the U.S. Office of Management and Budget. At Wave 1, 43,093 respondents 
(81.0% response rate) completed computer-assisted home interviews assessing substance use 
disorders, psychiatric disorders, and medical conditions. Three years later (mean=36.6 
months) at Wave 2, 34,653 of the eligible Wave 1 respondents (86.7% response rate) 
completed a second home interview. A total of 3,134 Wave 1 respondents were not eligible 
for Wave 2 due to being deceased, deported, mentally or physically impaired, or on active 
duty in the armed forces. Respondents who participated in Waves 1 and 2, versus Wave 1 
only, were younger (46.0 vs. 48.2 years) and more likely to be female (58.0% vs. 53.2%), to 
be non-Hispanic White (58.2% vs. 51.3%), to have a high school education or more (83.4% 
vs. 75.1%), and to have a lifetime depressive disorder (17.3% vs. 13.3%; all ps < .001). We 
applied three exclusion criteria to the Wave 2 sample. Respondents were excluded if: (1) 
CVD status at Wave 1 was positive (n=1,742) or missing (n=1,719), (2) CVD status at Wave 
2 was missing (n=1,065), or (3) CVD risk factors at Wave 1 were missing (n=1,401). 
Characteristics of our final sample of 28,726 adults are shown in Table 1.
Measures and Procedures
Lifetime Depressive Disorder Subtypes—Lifetime dysthymic disorder and MDD 
were determined by the Alcohol Use Disorder and Associated Disabilities Interview 
Schedule-IV (AUDADIS-IV), a fully structured diagnostic interview administered by lay 
interviewers assessing mental disorders using DSM-IV criteria (Ruan et al., 2008). 
NESARC personnel coded diagnostic variables for the past year and prior to the past year. 
We used the NESARC variables that excluded illness-induced and substance-induced 
disorders and ruled out bereavement (Grant et al., 2005). The AUDADIS-IV has 
demonstrated good test-retest reliability for depressive disorders (Grant et al., 2003) and 
generally good agreement with clinician evaluations (Hasin & Grant, 2015).
From the NESARC variables, we computed two variables. Our first variable, atypical 
depression, had four levels: no depressive disorder, dysthymic disorder only, nonatypical 
MDD, and atypical MDD. First, we classified respondents into no depressive disorder 
history (never met criteria), lifetime dysthymic disorder only (past year or prior), and 
lifetime MDD (past year or prior) groups. Those who met criteria for both lifetime 
dysthymic disorder and MDD were placed into the MDD group. Then, we further classified 
respondents with lifetime MDD. The atypical MDD group consisted of respondents with 
both hyperphagia and hypersomnia. We coded individuals as having hyperphagia if they 
answered “yes” to either of the following AUDADIS-IV questions: “During that time when 
your mood was at its lowest/you enjoyed or cared the least about things, did you gain at least 
2 pounds a week for several weeks or at least 10 pounds altogether within a month (other 
than when you were growing or pregnant)?” or “During that time…, did you find that you 
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wanted to eat a lot more than usual for no special reason, most days for at least 2 weeks?” 
We coded respondents as having hypersomnia if they answered “yes” to the AUDADIS-IV 
question, “During that time…, did you sleep more than usual nearly every day for at least 2 
weeks?” While other criteria for atypical MDD exist (APA, 2013), using only the reversed 
somatic-vegetative symptoms is a valid approach (Benazzi, 2002) and has been utilized in 
past studies (Blanco et al., 2012; Chou & Yu, 2013; Horwath, Johnson, Weissman, & 
Hornig, 1992; Matza, Revicki, Davidson, & Stewart, 2003).
Our second variable, double depression, also had four levels: no depressive disorder, 
dysthymic disorder only, MDD only, and double depression. The definitions for the no 
depressive disorder and dysthymic disorder groups were the same as above. Respondents 
with lifetime MDD were further classified into two groups: MDD only (if only lifetime 
MDD was present) and double depression (if both lifetime dysthymic disorder and MDD 
were present).
Incident Cardiovascular Disease—Using data from the NESARC Medical Conditions 
and Practices questionnaire administered at Wave 2, we computed an incident CVD variable 
comprised of new-onset arteriosclerosis, angina, or myocardial infarction (MI) based on 
self-reported physician diagnoses. In Part A, respondents were asked, “In the last 12 months, 
did you have: (1) hardening of the arteries or arteriosclerosis? (2) chest pain or angina 
pectoris? (3) a heart attack or myocardial infarction?” If the answer to Part A was “yes,” in 
Part B respondents were asked, “Did a doctor or other health professional tell you that you 
had (name of condition)?” We coded respondents as positive for incident CVD if they 
answered “yes” to Parts A and B for at least one CVD question, and we coded respondents 
as negative if they answered “no” to all three Part A questions. Those who were coded as 
“unknown” for Part A or B for one or more questions and who did not answer “yes” to Part 
A and B for at least one question were coded as missing for incident CVD and were 
excluded. To compute a corresponding baseline CVD variable, we applied the same coding 
scheme to the identical Wave 1 CVD questions. Because our focus is predicting new-onset 
CVD, we included only respondents coded negative for baseline CVD.
Potential Confounders—The following variables – which could operate as potential 
confounders of depression-CVD associations (Luger, Suls, & Vander Weg, 2014; Luppino et 
al., 2010; Nouwen et al., 2010) – were included as control variables in the models: age 
(years), sex (0=male, 1=female), race/ethnicity, education level, hypertension, 
hypercholesterolemia, diabetes, tobacco use, body mass index (BMI), and lifetime anxiety 
disorder. These variables were based on self-reported data from Wave 1 except 
hypercholesterolemia and diabetes, which were assessed only at Wave 2. We recoded race/
ethnicity into a four-level variable (0=non-Hispanic White, 1=non-Hispanic Black, 
2=Hispanic or Latino, 3=Other). Next, we created three dummy-coded variables using non-
Hispanic White as the reference category. Education level was assessed by the question, 
“Highest grade or year of school completed?” From these data, we computed a 4-level 
variable (0=less than high school, 1=high school or equivalent, 2=some college or 
Associate’s degree, 3=Bachelor’s degree or higher). Three dummy-coded variables using 
less than high school as the reference category were then created.
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We coded respondents as positive for hypertension, hypercholesterolemia, and diabetes, 
respectively, if they answered “yes” to “In the past 12 months, have you had: (1) high blood 
pressure or hypertension? (2) high cholesterol? (3) diabetes or sugar diabetes?” and “yes” to 
“Did a doctor or other health professional tell you that you had (name of condition)?” We 
coded respondents as negative for each condition if they answered “no” to the first question. 
Those coded by NESARC personnel as “unknown” for either question were coded as 
missing for that condition and were excluded. We recoded NESARC’s tobacco use variable 
(current user, former user, lifetime nonuser) into a dichotomous variable (0=current nonuser, 
1=current user). BMI (kg/m2) was computed from self-reported height and weight.
We computed a lifetime anxiety disorder variable using AUDADIS-IV data collected at 
Wave 1. Respondents who were coded by NESARC personnel as meeting diagnostic criteria 
for panic disorder, agoraphobia, generalized anxiety disorder, or social phobia in the past 
year or prior (illness- and substance-induced disorders excluded) were coded as positive for 
lifetime anxiety disorder. Those not meeting criteria for any of these disorders were coded as 
negative.
Data Analysis
We ran three sets of logistic regression analyses – demographics-adjusted, CVD risk factor-
adjusted, and anxiety disorder-adjusted – examining the atypical depression variable as a 
predictor of incident CVD. For each set, we ran three models, each of which used a different 
reference category (1 = no depressive disorder, 2 = dysthymic disorder only, 3 = nonatypical 
MDD). Control variables in the demographics-adjusted models were age, sex, race/ethnicity, 
and education level. The CVD risk factor-adjusted models were further adjusted for 
hypertension, hypercholesterolemia, diabetes, tobacco use, and BMI. The anxiety disorder-
adjusted models additionally included lifetime anxiety disorder. Finally, we ran an identical 
series of logistic regression analyses for the double depression variable. All selected control 
variables were significantly associated with the atypical depression and double depression 
variables.
Analyses were conducted with SAS statistical software, version 9.3. Models were weighted 
to account for oversampling, probabilities of selection, and nonresponse. Weighted analyses 
provide estimates for U.S. civilian noninstitutionalized population based on the 2000 
Decennial Census (Hasin & Grant, 2015).
Results
Depressive Disorder Subtypes and Incident Cardiovascular Disease
The lifetime prevalence was 3.4% (964 cases) for atypical MDD and 3.1% (833 cases) for 
double depression. The degree of overlap between these two subtypes was modest, as the phi 
coefficient (rϕ) was 0.22, and 228 cases qualified for both atypical MDD and double 
depression. We identified 1,116 cases (3.9%) of incident CVD: 264 with arteriosclerosis 
only, 625 with angina only, 75 with MI only, 53 with arteriosclerosis and angina, 11 with 
arteriosclerosis and MI, 58 with angina and MI, and 30 with all three outcomes. Tables 2 and 
3 display the number of CVD cases and the unadjusted case rate for each depressive disorder 
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subtype. Due to its smaller size, the dysthymic disorder only group had a low number of 
CVD cases, which reduced power for comparisons involving this group.
Atypical Depression as a Predictor of Incident Cardiovascular Disease
Demographics-adjusted logistic regression models (Table 2) revealed that respondents with 
atypical MDD had over twice the odds of incident CVD than those with no depressive 
disorder (p<.001). Although adults with dysthymic disorder only (37% greater odds; p=.043) 
or nonatypical MDD (51% greater odds; p<.001) were more likely to develop CVD than 
nondepressed adults, the magnitude of these associations was less than half of that for 
atypical MDD. These models also indicated that the odds of CVD in the atypical MDD 
group were greater than in the dysthymic disorder only (OR=1.61, 95% CI: 1.08–2.39, p=.
019) and nonatypical MDD (OR=1.46, 95% CI: 1.11–1.91, p=.006) groups.
CVD risk factor-adjusted and anxiety disorder-adjusted models (Table 2) yielded a similar 
pattern of results, although associations were attenuated and some fell short of significance. 
Respondents with atypical MDD remained at the highest risk of incident CVD, with a 78% 
(p<.001) and 56% (p=.001) greater odds than nondepressed adults. However, comparisons of 
the atypical MDD group with the dysthymic disorder only group (CVD risk factor-adjusted 
OR=1.46, 95% CI: 0.97–2.18, p=.068; anxiety disorder-adjusted OR=1.39, 95% CI: 0.92–
2.09, p=.12) and the nonatypical MDD group (CVD risk factor-adjusted OR=1.25, 95% CI: 
0.94–1.65, p=.13; anxiety disorder-adjusted OR=1.22, 95% CI: 0.92–1.61, p=.18) were no 
longer significant. In the CVD risk factor-adjusted and anxiety disorder-adjusted models, 
nonatypical MDD also continued to predict incident CVD (p<.001 and p=.004), whereas 
dysthymic disorder did not (p=.21 and .48).
Double Depression as a Predictor of Incident Cardiovascular Disease
Demographics-adjusted models (Table 3) indicated that respondents those with double 
depression had more than twice the odds of incident CVD than nondepressed adults (p<.
001). Dysthymic disorder only (36% greater odds; p=.044) and MDD only (49% greater 
odds; p<.001) also predicted incident CVD but these relationships were not as strong as that 
for double depression. The double depression group also had higher odds of incident CVD 
than the dysthymic disorder only (OR=1.59, 95% CI: 1.16–2.19, p=.004) and MDD only 
(OR=1.46, 95% CI: 1.20–1.77, p<.001) groups.
Although associations were again attenuated, the pattern of results was similar in the CVD 
risk factor-adjusted and anxiety disorder-adjusted models (Table 3). Adults with double 
depression remained at the highest odds of incident CVD. This group had a 95% (p<.001) 
and 65% (p<.001) greater odds than those in the no depressive disorder group, and 
comparisons with the dysthymic disorder only group (CVD risk factor-adjusted OR=1.61, 
95% CI: 1.16–2.21, p=.004; anxiety disorder-adjusted OR=1.47, 95% CI: 1.07–2.02, p=.
018) and the MDD only group (CVD risk factor-adjusted OR=1.42, 95% CI: 1.16–1.73, p=.
001; anxiety disorder-adjusted OR=1.31, 95% CI: 1.08–1.59, p=.006) continued to be 
significant. In the CVD risk factor-adjusted and anxiety disorder-adjusted models, MDD 
only (p<.001 and p=.016) – but not dysthymic disorder only (p=.22 and .48) – remained a 
predictor of incident CVD.
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Discussion
Our examination of the NESARC data indicates that atypical MDD and double depression 
are two depressive disorder subtypes that may be particularly strong predictors of new-onset 
CVD. With respect to atypical MDD, U.S. adults with a lifetime history of this subtype had 
a higher odds of incident CVD than those with no depression history, dysthymic disorder 
only, or nonatypical MDD in demographics-adjusted models. Although a similar pattern of 
results was observed in CVD risk factor-adjusted models, some comparisons fell short of 
significance. Concerning double depression, U.S. adults with a lifetime history of subtype 
had a higher odds of incident CVD than those with no depression history, dysthymic 
disorder only, or MDD only in both demographics- and CVD risk factor-adjusted models. 
Further adjustment for lifetime anxiety disorder attenuated associations but did not alter the 
pattern of results for either subtype. The modest degree of overlap between atypical MDD 
and double depression suggests that their associations with incident CVD likely reflect 
separate relationships; however, the 228 cases with both subtypes did contribute to both 
relationships. Collectively, our findings indicate that adults with atypical MDD or double 
depression may be subgroups of the depressed population at greatest risk of developing 
CVD and, thus, may be driving the overall depression-CVD relationship.
Our study addresses a key gap in the literature – i.e., the absence of prospective studies 
examining atypical depression or double depression as predictors of incident CVD. Our 
findings do conflict with three prior studies that observed no difference in prevalent CVD 
between depressed adults with versus without atypical features (Niranjan, et al., 2012) and 
no associations between atypical MDD symptoms and prevalent CVD (Fraguas, et al., 2007; 
Vogelzangs, et al., 2010). However, due to their cross-sectional design, reverse causality may 
have obscured depression subtype differences (Spijkerman, et al., 2005). To our knowledge, 
there are no previous studies that have examined associations between double depression 
and CVD risk markers or outcomes. Although one other prospective analysis of the 
NESARC data reported the association of lifetime MDD with CVD, the focus of that 
analysis was the bipolar disorder-incident CVD relationship, and depressive disorder 
subtypes were not examined (Goldstein, Schaffer, Wang, & Blanco, 2015).
There are multiple candidate mechanisms that could explain why atypical MDD may be a 
stronger predictor of incident CVD. Evidence suggests that conventional CVD risk factors 
are elevated in adults with atypical versus nonatypical depression (Chou & Yu, 2013; Cizza, 
et al., 2012; Glaus, et al., 2013; Lamers, et al., 2013; Levitan, et al., 2012; Niranjan, et al., 
2012; Takeuchi, et al., 2013; van Reedt Dortland, et al., 2010). Moreover, atypical MDD has 
been found to predict incident obesity and increases in BMI, waist circumference, and fat 
mass over time (Lasserre, et al., 2014). In our models adjusting for Wave 1 CVD risk factors, 
associations were attenuated. However, because depressive disorders and CVD risk factors 
were assessed at the same point, the NESARC data cannot be used to determine whether the 
CVD risk factors were operating as confounders or mediators. Given that our objective was 
to provide unbiased estimates of the associations between depressive disorder subtypes and 
incident CVD, we chose to treat the CVD risk factors as potential confounders to be 
conservative. In addition to conventional CVD risk factors, other mechanisms may also be at 
work. Another candidate mechanism, which was not assessed in NESARC, is greater 
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systemic inflammation. Adults with atypical depression, versus those with nonatypical 
depression, have been found to have higher circulating levels of inflammatory markers 
predictive of CVD, such as C-reactive protein and interleukin-6 (Hickman, et al., 2014; 
Lamers, et al., 2013; Rudolf, et al., 2014). Two other candidate mechanisms are poor diet 
quality (Rahe et al., 2015) and low physical activity (Glaus, et al., 2013; Matza, et al., 2003). 
In addition to these biological and behavioral pathways, adults with atypical MDD may have 
greater lifetime exposure to depression, given that it is characterized by earlier age of onset, 
more severe symptoms, and a greater number of episodes (Blanco, et al., 2012; Matza, et al., 
2003; Novick et al., 2005).
Less is known about the correlates of double depression that could be operating as 
underlying mechanisms. Like atypical depression, associations were attenuated after 
adjustment for conventional CVD risk factors, suggesting that they may partially explain the 
elevated CVD risk of this group. It is also plausible that double depression is a stronger 
predictor of incident CVD on account of its longer duration and higher recurrence rate than 
MDD alone and its greater symptom severity than dysthymia alone (Keller, et al., 1997), 
resulting in greater lifetime exposure to depression and the associated atherogenic biological 
and behavioral changes (Grippo & Johnson, 2002; Joynt, Whellan, & O’Connor, 2003). In 
addition, a smaller study found that patients with double depression reported greater 
hopelessness than patients with MDD or dysthymia (Joiner, Cook, Hersen, & Gordon, 
2007). Hopelessness has been linked with greater subclinical atherosclerosis (Whipple et al., 
2009) and an increased risk of CVD events (Everson et al., 1996), independent of depressive 
symptoms. Clearly, there is a need for studies examining associations of double depression 
with CVD outcomes and candidate mechanisms.
The present study has key strengths, including the longitudinal design, large nationally 
representative sample, and structured interview assessments of psychiatric disorders. 
NESARC is the largest and most comprehensive psychiatric epidemiologic survey 
conducted in the U.S (Hasin & Grant, 2015), and its prospective data allowed us to draw 
strong inferences regarding directionality. Our study also has limitations that should be 
considered. First, epidemiologic surveys often assess CVD by self-report of physician 
diagnoses. Supporting this approach, agreement between self-reported and medical record-
ascertained CVD has been found to be acceptable to good (Barr, Tonkin, Welborn, & Shaw, 
2009; Bergmann, Byers, Freedman, & Mokdad, 1998; Heckbert et al., 2004; Lampe, Walker, 
Lennon, Whincup, & Ebrahim, 1999; Machon et al., 2013; Okura, Urban, Mahoney, 
Jacobsen, & Rodeheffer, 2004). A recent study (Yasaitis, Berkman, & Chandra, 2015) 
comparing self-reported and Medicare claims-identified MIs did observe lower agreement 
than past studies; however, the authors speculated that this may have been due to their 
sample’s older age and their narrower MI definition. Nonetheless, because some degree of 
misclassification occurs with self-reports of physician diagnoses, there is a need for future 
studies examining depressive disorder subtypes as predictors of incident CVD adjudicated 
by a review of medical records. Second, incident fatal CVD events were not captured. 
Respondents who died between Waves 1 and 2 of NESARC were excluded from the Wave 2 
cohort, and information regarding cause of death is not available. While this could have 
compromised power, that does not appear to be the case, as we observed 1,116 cases of 
incident CVD. Third, some incident nonfatal MIs may have not have been detected because 
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the NESARC Wave 2 questions inquired about CVD diagnoses in the past 12 months only. 
This is less of a concern for arteriosclerosis and angina, as these are chronic conditions and 
not discrete events. Our composite incident CVD outcome also reduces the potential for 
misclassification, given that respondents who suffered nonfatal MIs between Waves 1 and 2, 
but prior to the past 12 months, may have also been diagnosed with one of the other CVD 
conditions during follow-up. Fourth, due to the limited temporal resolution of the diagnostic 
variables, our double depression definition did not take into account the order of onset or co-
occurrence of dysthymic disorder and MDD. Future studies with diagnostic variables 
possessing greater temporal resolution are needed to examine the importance of these 
characteristics in predicting incident CVD. Fifth, although age ranged from 18 to 97 years in 
our sample, the mean age was only 45 years, and the follow-up period was only three years. 
Both of these factors likely contributed to the lower rate (3.9%) of incident CVD.
Conclusion
We report prospective evidence from a nationally representative sample indicating that U.S. 
adults with atypical MDD or double depression may be subgroups of the depressed 
population at particularly high risk of new-onset CVD who may be driving the depression-
CVD relationship. With respect to research implications, our results suggest that clinical 
trials evaluating whether successful depression treatment reduces CVD risk should consider 
specifically recruiting patients with atypical MDD or double depression, as it is in these 
subgroups where most of the excess CVD risk seems to reside. Furthermore, our findings 
underscore the need to continue to test existing treatments (Fournier et al., 2013) or to 
develop new treatments to address residual depressive symptoms and syndromes, such as 
reversed somatic-vegetative symptoms and dysthymia. Concerning clinical practice, our 
results highlight the potential importance of depression screening that allows for depressive 
disorder subtyping. Finally, our findings raise the possibility that CVD primary prevention 
efforts should be initiated earlier and/or intensified among adults with atypical MDD or 
double depression to prevent or delay clinical CVD onset, thereby reducing the excess CVD 
burden of the depressed population.
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Table 1
Characteristics of Respondents (N = 28,726)
Demographic Factors
Age, years (SD) 44.8 (17.0)
Female, % 57.5
Race/Ethnicity
  Non-Hispanic White, % 58.2
  Non-Hispanic Black, % 18.6
  Hispanic/Latino, % 18.7
  Other, % 4.5
Education Level
  Less than High School, % 15.2
  High School or Equivalent, % 28.5
  Some College or Associate’s Degree, % 30.6
  Bachelor’s Degree or Higher, % 25.7
Cardiovascular Risk Factors
Hypertension, % 18.2
Hypercholesterolemia, % 19.3
Diabetes, % 8.0
Tobacco Use, % 25.6
Body Mass Index, kg/m2 27.0 (5.6)
Anxiety Disorders
Lifetime Anxiety Disorder, % 10.5
Note. Continuous variables are presented as mean (standard deviation), and categorical variables are presented as percentage. Lifetime anxiety 
disorder consists of panic disorder, agoraphobia, generalized anxiety disorder, and social phobia.
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